Cost Of Second-Line ARVs A ‘Huge Barrier To Care’ In Resource-Poor Countries
In this U.N. Dispatch blog post, Mark Leon Goldberg, managing editor of the blog, examines the costs of second-line antiretroviral treatments (ARVs), which "are several orders of magnitude more expensive than traditional, first-line ARV treatments" and are a "huge barrier to providing care" for resource-poor countries. He writes of "a huge gap in the way governments and donors have historically approached people living with HIV," adding that "as more people access first-line treatment, there will be more opportunities for people to develop resistance to that first line. Donors and governments in the developing world simply can't afford that kind of outlay."